Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER networkLoreta A. Kondili, Stefano Vella, Giovanni Battista Gaeta et al.|PLoS ONE|2017Cited by 114
Forecasting Hepatitis C liver disease burden on real‐life data. Does the <i>hidden iceberg</i> matter to reach the elimination goals?Loreta A. Kondili, Sarah Robbins Scott, Sarah Blach et al.|Liver International|2018Cited by 45
A prospective study of direct‐acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohortLoreta A. Kondili, Anna Linda Zignego, Monica Monti et al.|Hepatology|2021Cited by 36
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trialMassimiliano Fabbiani, A D’Avino, Emanuele Focà et al.|Journal of Antimicrobial Chemotherapy|2018Cited by 33
Modeling cost‐effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real‐life cohortLoreta A. Kondili, Federica Romano, Francesca Romana Rolli et al.|Hepatology|2017Cited by 29